In recent years, chemotherapy-induced cardiovascular disease has emerged as a significant cause of mortality among cancer survivors. Anthracyclines, pivotal in treating cancers like breast cancer and ...

Therapeutic advances have resulted in a growing population of childhood cancer survivors. Unfortunately, this success comes at a price. A substantial proportion of the survivors develop ...

The AHA has published a scientific statement regarding cardiovascular toxicity in patients with history of treatment for childhood cancer.

Panelists discuss how cardiovascular toxicity remains a significant concern with certain tyrosine kinase inhibitors (TKIs) used in chronic myeloid leukemia (CML) treatment, particularly with the older ...

Panelists discuss how eliminating the strict mealtime restrictions with the new nilotinib formulation addresses a significant unmet need in chronic myeloid leukemia (CML) treatment by reducing ...

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business ...

Emerging therapeutic strategies have targeted this axis, including liproxstatin-1-mediated lipid radical quenching and dexrazoxane-driven iron chelation, which have shown promise in preserving ...